Status:
UNKNOWN
Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²)
Lead Sponsor:
Weprom
Conditions:
Myeloma
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Therapeutic intensification followed by an autograft of hematopoietic stem cells is a standard of care for young patients with myeloma from the first line and for lymphoma from the second or third lin...
Eligibility Criteria
Inclusion
- Age ≥ 18 years,
- Patient with lymphoma or myeloma justifying an autograft of hematopoietic stem cells whatever the line of treatment,
- Patient affiliated to a social security scheme,
- Patient who has given written consent before any specific procedure related to the study
Exclusion
- Central and / or peripheral neurological deficit not allowing adapted physical activity sessions to be carried out,
- Uncontrolled hypertension,
- Left ventricular Ejection Fraction \<50%,
- Chronic respiratory insufficiency with alterations in the functional respiratory investigations,
- Active viral infection: hepatitis B, C and HIV,
- Pregnancy or breastfeeding,
- Persons deprived of their liberty or under guardianship
- Dementia, mental alteration or psychiatric pathology which could compromise the patient's informed consent and / or compliance with the protocol and follow-up of the trial,
- Patient who can't follow protocol for psychological, social, family or geographic reasons.
Key Trial Info
Start Date :
November 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04320420
Start Date
November 20 2020
End Date
October 1 2024
Last Update
October 8 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Angers, France
2
Centre Jean Bernard/Clinique Victor Hugo
Le Mans, France